Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 277
Selected: 0
NCT IDTitle
NCT01241760VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
NCT00003847VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
NCT02070744Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
NCT03163511A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
NCT00457821Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
NCT01554085First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
NCT06336096A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine
NCT05418712A Microneurography (MNG) Study of VX-150 in Healthy Participants
NCT06926621A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
NCT04043806A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
NCT02660424A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee
NCT01216046Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
NCT01459913Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
NCT03783286Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects
NCT00621296Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
NCT04618185Gut Imaging for Function & Transit in CF - GIFT-CF 3
NCT05866055A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults
NCT01807923A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
NCT01381289VX-770 Expanded Access Program
NCT01994486Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1
NCT06615570A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants
NCT05422222Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT00251199VX-950 and Peginterferon for Hepatitis C
NCT03029455A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT06861413A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
NCT06508762A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
NCT07204275A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT01516918A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
NCT00627926A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
NCT01561807A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
NCT02725567A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
NCT05951205Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype
NCT01275599Drug-Drug Interaction Study Between Telaprevir and Buprenorphine
NCT04545515A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
NCT05274269Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
NCT01501383A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
NCT05579431A Phase 1, First-in-human Study of VX-634
NCT03655678A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
NCT05704556Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment
NCT06529796Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment
NCT02343445Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)
NCT06147778Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
NCT06154447Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
NCT05153317Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
NCT01863238An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
NCT00500812A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries
NCT00780416Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
NCT05111145A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
NCT03338595Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
NCT05643495A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype